Edap Tms (NASDAQ:EDAP) versus Nexalin Technology (NASDAQ:NXL) Financial Comparison

Nexalin Technology (NASDAQ:NXLGet Free Report) and Edap Tms (NASDAQ:EDAPGet Free Report) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

0.6% of Nexalin Technology shares are held by institutional investors. Comparatively, 62.7% of Edap Tms shares are held by institutional investors. 27.7% of Nexalin Technology shares are held by insiders. Comparatively, 0.2% of Edap Tms shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Nexalin Technology and Edap Tms, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexalin Technology 0 0 0 0 N/A
Edap Tms 0 0 2 0 3.00

Edap Tms has a consensus target price of $14.00, indicating a potential upside of 398.22%. Given Edap Tms’ higher probable upside, analysts plainly believe Edap Tms is more favorable than Nexalin Technology.

Volatility and Risk

Nexalin Technology has a beta of 5.66, suggesting that its share price is 466% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nexalin Technology and Edap Tms”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nexalin Technology $150,159.00 49.78 -$4.65 million ($0.66) -1.07
Edap Tms $62.05 million 1.68 -$22.92 million ($0.54) -5.20

Nexalin Technology has higher earnings, but lower revenue than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nexalin Technology and Edap Tms’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexalin Technology -3,578.81% -213.51% -173.41%
Edap Tms -31.68% -36.41% -22.25%

Summary

Edap Tms beats Nexalin Technology on 8 of the 13 factors compared between the two stocks.

About Nexalin Technology

(Get Free Report)

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Edap Tms

(Get Free Report)

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.

Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.